Johnson & Johnson (NYSE:JNJ – Get Free Report) shares traded down 2.1% during trading on Wednesday. The stock traded as low as $272.58 and last traded at $272.7460. Approximately 7,790,841 shares traded hands during mid-day trading, a decline of 2% from the average daily volume of 7,957,331 shares. The stock had previously closed at $278.70.
Key Headlines Impacting Johnson & Johnson
Here are a few of the latest headlines about JNJ:
- Positive Sentiment: J&J plans to acquire Ollin Biosciences, adding a Phase III candidate for retinal diseases to its ophthalmology pipeline. Blackstone is expected to provide $750 million toward development costs. The asset could support growth beyond 2030, though it still needs to succeed in clinical development and compete in a crowded market. J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition
- Neutral Sentiment: The reported average analyst price target is $275.92, close to the $273.63 price cited in the background information, suggesting limited implied upside at that snapshot. Johnson & Johnson Stock Has Average Price Target of $275.92
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J tied to its talc baby powder. Separately, Pomerantz LLP said it is investigating potential investor claims, keeping litigation risk in focus. Louisiana Appeals Court Upholds Damages in Mesothelioma Case Pomerantz Law Firm Investigates Investor Claims
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. HSBC upped their price objective on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Leerink Partners reduced their target price on Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Erste Group Bank cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Finally, Bank of America reiterated a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.
Check Out Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Stock Down 2.1%
The firm has a 50 day moving average of $267.31 and a two-hundred day moving average of $250.38. The stock has a market capitalization of $656.58 billion, a PE ratio of 41.33, a P/E/G ratio of 2.79 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the company earned $2.80 earnings per share. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.
Insider Activity
In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company’s stock.
Institutional Investors Weigh In On Johnson & Johnson
A number of large investors have recently bought and sold shares of JNJ. Outlook Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at $28,000. Matrix Trust Co boosted its position in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares during the period. Navigoe LLC boosted its position in Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after acquiring an additional 55 shares during the period. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $43,000. Finally, Hanseatic Management Services Inc. purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
